Zobrazeno 1 - 5
of 5
pro vyhledávání: '"59"'
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 145:1857-1864
To evaluate the value of concurrent chemotherapy after induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma (NPC) in the era of intensity-modulated radiation therapy (IMRT), we performed this retrospective cohort study to compa
Autor:
A. Saidi, Mahmut Ozsahin, Jean Bourhis, D. Hahnloser, M. Montemurro, Maira Biggiogero, Alessandra Franzetti-Pellanda, Michele Zeverino, De Bari B
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Journal of cancer research and clinical oncology, vol. 145, no. 4, pp. 1075-1084
Journal of cancer research and clinical oncology, vol. 145, no. 4, pp. 1075-1084
Purpose Helical tomotherapy (HT) has been recently introduced in the neoadjuvant treatment of locally advanced rectal cancer. Aim of this study is to report the toxicity and local control rates of a large series of locally advanced rectal cancer pati
Autor:
Jai Young Cho, Kwhanmien Kim, Sukki Cho, Sang A. Kim, Duck Woo Kim, Ji Won Kim, Jee Hyun Kim, Heung Kwon Oh, Won Chang, Sanghoon Jheon, Koung Jin Suh, Sung Bum Kang, Jin Won Kim, Keun Wook Lee
Publikováno v:
Journal of cancer research and clinical oncology. 146(9)
Some metastatic colorectal cancer (mCRC) patients receive conversion surgery (CS), including metastasectomy after palliative chemotherapy. Although targeted agents significantly improved the outcomes, the clinical outcome of CS in the targeted agent
Autor:
Manuel Valladares-Ayerbes, Julien Taieb, Javier Gallego, Michael Geissler, Reija Koukakis, Fernando Rivera, Gaston Demonty, Meinolf Karthaus, Marc Peeters, Salvatore Siena
Publikováno v:
Journal of cancer research and clinical oncology
Journal of Cancer Research and Clinical Oncology
Journal of Cancer Research and Clinical Oncology
Purpose To report exploratory analyses of early tumour shrinkage (ETS) and depth of response (DpR) in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC), receiving the first-line treatment in three randomised panitumumab trials. Met
Autor:
Sebastian Scholl, Thomas Ernst, Max Desole, Herbert G. Sayer, Lars-Olof Mügge, Inken Hilgendorf, Andreas Hochhaus, Christa Kunert, Nils Winkelmann
Publikováno v:
Journal of cancer research and clinical oncology. 142(12)
Even in the era of proteasome inhibitors and immunomodulatory drugs, the autologous stem cell transplantation after high-dose melphalan continues to represent a standard approach for myeloma patients in first-line therapy. Different mobilization chem